drugset / Trial / NCT05308030
Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization
NaSingle-groupDouble-blindTreatment
Summary
Assessing the outcomes of using Rivaroxaban plus Aspirin in patients with Lower Extremity Peripheral Arterial Disease after Endovascular Revascularization
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-05
- Completion
- 2023-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 100 mg | — |
| Subject | Rivaroxaban | Other / unclassified | 2.5 mg | — |